Tus-Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 000590.SZ

Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 15.45%

Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin is 15.45% for the year ending December 31, 2023, a 11.79% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 13.82%, a -33.46% change year over year.
Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 20.77%, a 34.67% change year over year.
Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 15.42%, a -31.49% change year over year.
Tus-Pharmaceutical Group Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 22.51%, a 350.58% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shenzhen Stock Exchange: 000590.SZ

Tus-Pharmaceutical Group Co., Ltd.

CEO	Ms. Ting Tang
IPO Date	Jan. 19, 1996
Location	China
Headquarters	No. 33, Yangliu Road
Employees	1,237
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Consumer Packaged Goods Cosmetics Drugstores & Retail Pharmacies Personal Care Tobacco

Description

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.

Key trends

Past 5 years